What is the Share Price of Concord Biotech Ltd?
- Answer Field
-
The share price of Concord Biotech Ltd for NSE is ₹ 1518.6 and for BSE is ₹ 1515.
BAJAJ BROKING
Experience smart and hassle-free investing in minutes with Bajaj Broking! *T&C apply
As of the latest trading session, CONCORD BIOTECH LIMITED share price is currently at ₹ 1518.6, which is down by ₹ -39.20 from its previous closing. Today, the stock has fluctuated between ₹ 1510.10 and ₹ 1583.00. Over the past year, CONCORD BIOTECH LIMITED has achieved a return of -5.61 %. In the last month alone, the return has been -6.32 %. Read More...
Particulars | DEC 2024 (Values in Cr) |
---|---|
Revenue | 244.22 |
Operating Expense | 159.63 |
Net Profit | 74.09 |
Net Profit Margin (%) | 30.33 |
Earnings Per Share (EPS) | 7.08 |
EBITDA | 112.67 |
Effective Tax Rate (%) | 25.40 |
Company Name | Price | P/E | P/B | Market Cap | 52 Week Low/High |
---|---|---|---|---|---|
AMBALAL SARABHAI ENTERPRISES L | 37.10 | 19.95 | 2.02 | 284.31 | 34.11 / 77.70 |
BLISS GVS PHARMA LTD | 122.65 | 16.07 | 1.27 | 1292.37 | 92.25 / 184.95 |
CIPLA LTD | 1541.00 | 24.94 | 4.38 | 124457.39 | 1310.05 / 1702.00 |
FERMENTA BIOTECH LIMITED | 272.25 | 22.56 | 2.76 | 801.26 | 145.00 / 449.00 |
Company Name | Price | P/E | P/B | Market Cap | 52 Week Low/High |
---|---|---|---|---|---|
AMBALAL SARABHAI ENTERPRISES L | 37.10 | 22.35 | 6.30 | 284.31 | 34.11 / 77.70 |
AMRUTAJAN HEALTH LTD | 679.10 | 39.81 | 6.59 | 1963.32 | 548.05 / 861.40 |
ASTRAZENECA PHARMA IND LT | 8795.90 | 131.18 | 32.36 | 21989.75 | 5000.00 / 9199.00 |
BLISS GVS PHARMA LTD | 122.65 | 15.93 | 1.26 | 1292.37 | 92.25 / 184.95 |
Concord Biotech Limited was originally incorporated as Servomed Pharmaceuticals Private Limited' at Ahmedabad, Gujarat as a Private Limited Company dated November 23, 1984, issued by the Registrar of Companies. Thereafter, name of the Company was changed to Concord Biotech Limited' dated February 16, 2001, which became a Public Company and a fresh Certificate of Incorporation dated November 7, 2001 was issued by the RoC.
The Company is an India-based bio pharma and one of the leading global developers and manufacturers of select fermentation-based APIs across immunosuppressants and oncology in terms of market share, based on volume in supplying to over 70 countries including regulated markets, such as the United States, Europe and Japan, and India. Presently, it is engaged in research and development, manufacturing, marketing and selling of pharmaceutical products. Its API manufacturing facilities are located at Dholka and Limbasi, and formulations facility at Valthera in Gujarat.
In 2000, the Company was acquired by the Promoter, Mr. Sudhir Vaid.
In 2016, the Company launched formulation business in India as well as emerging markets, including Nepal, Mexico, Indonesia, Thailand, Ecuador, Kenya, Singapore and Paraguay, and have further expanded to the United States. It established a facility at Valthera, Gujarat.
It set up a joint venture in Japan to grow business in 2018.
In 2019, the Company received two ANDA approvals. It expanded their business into critical care segment in India. It commenced marketing of Mycophenolate Mofetil Capsules USP 250 mg.
In 2020, Mycophenolate Sodium Tablets got launched in the US market.
The Company added a new manufacturing unit at Limbasi, which commenced operations in July, 2021.
As of March 31, 2022, the Company had 6 fermentation-based immunosuppressant APIs, including tacrolimus, mycophenolate mofetil, mycophenolate sodium, cyclosporine, sirolimus and pimecrolimus. It had 3 manufacturing facilities in the state of Gujarat, India, comprising API manufacturing facilities in Dholka and Limbasi and a formulation manufacturing facility in Valthera, which were commercialized in 2000, 2021 and 2016, respectively. Their total annual installed fermentation capacity for APIs was 1,250 m3, as of March 31, 2022. It had a total of 41 manufacturing blocks and 387 reactors in the Dholka and Limbasi facilities.
In August 2023, Company made an Initial Public Offer by issuing 20,925,652 Equity Shares aggregating to Rs 1551 Crores through Offer for Sale.
The Company has launched 21 new formulations products in 2024.
The share price of Concord Biotech Ltd for NSE is ₹ 1518.6 and for BSE is ₹ 1515.
The market cap of Concord Biotech Ltd for NSE is ₹ 1,58,87.02 Cr. and for BSE is ₹ 1,58,49.36 Cr. as of now.
The 52 Week High and Low of Concord Biotech Ltd for NSE is ₹ 2664.00 and ₹ 1327.05 and for BSE is ₹ 2658.00 and ₹ 1326.90.
You can trade in Concord Biotech Ltd shares with Bajaj Broking by opening a Demat Account.
The 1 year returns on the stock has been -5.61%.
Concord Biotech Ltd share price is for NSE ₹ 1518.6 & for BSE ₹ 1515 as on Apr 30 2025 03:30 PM.
The market cap of Concord Biotech Ltd for NSE ₹ 1,58,87.02 & for BSE ₹ 1,58,49.36 as on Apr 30 2025 03:30 PM.
As on Apr 30 2025 03:30 PM the price-to-earnings (PE) ratio for Concord Biotech Ltd share is 49.65.
As on Apr 30 2025 03:30 PM, the price-to-book (PB) ratio for Concord Biotech Ltd share is 152.04.
You can trade in Concord Biotech Ltd shares with Bajaj Broking by opening a demat account.
To buy Concord Biotech Ltd shares on the Bajaj Broking app, follow these steps:
• Login to the Bajaj Broking App
• Click on the Search Icon
• Search “Concord Biotech Ltd”
• Click on the BUY icon
• Place a buy order specifying the desired quantity of shares.
• Click BUY again to complete the purchase
No results found